Tropical medicine and health · 2026
Antileishmanial potential of polar fractions from Amaranthus blitoides S. Watson, Caucalis platycarpos L., and Cistanche flava (C.A.Mey.) Korsh.: evidence from in vitro and in vivo studies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miri Mohadese, Pasdaran Ardalan, Bahreini Mohammad Saleh, Dehghanian AmirReza, Sarkari Bahador, Dastan Naghmeh, Karimi Faeze, Karimi Kambiz, Javanmardi-Nia Negin, Motazedian Mohammad Hossein
Аннотация
BACKGROUND: Cutaneous leishmaniasis (CL) is recognized by the World Health Organization (WHO) as a research priority, yet its treatment remains challenging. CL lesions arise from complex interactions between the parasite and host immunity, where excessive inflammation can delay healing. Given the anti-inflammatory and immunomodulatory properties of medicinal plants, this study evaluated the effects of polar fractions from methanolic extracts of Amaranthus blitoides S. Watson, Caucalis platycarpos L., Cistanche flava (C.A.Mey.) Korsh., and their mixtures on CL caused by Leishmania major.
METHODS: In vitro, the antileishmanial activity of polar fractions against L. major promastigotes and their cytotoxicity on RAW 264.7 macrophages were assessed using flow cytometry and MTT assay, respectively. In vivo, female BALB/c mice infected with L. major were treated with polar fractions. Lesion size was monitored weekly, and at the end of treatment, parasite load at lesion margins and seven liver biochemical parameters in serum were measured.
RESULTS: Polar fractions exhibited mild-to-moderate antileishmanial effects on promastigotes without significant cytotoxicity to macrophages. In vivo, treatment with 20 mg/kg C. platycarpos, 20 mg/kg C. flava, and 80 mg/kg of the mixture significantly reduced lesion size compared to controls. Clinical observations also indicated reduced local inflammation in these groups. Parasite load remained detectable across all groups, and liver biochemical parameters did not differ significantly from the negative control.
CONCLUSION: Polar fractions of the studied plants demonstrated safety and therapeutic promise, supporting their potential as adjunctive candidates for further investigation in the management of CL caused by L. major.
METHODS: In vitro, the antileishmanial activity of polar fractions against L. major promastigotes and their cytotoxicity on RAW 264.7 macrophages were assessed using flow cytometry and MTT assay, respectively. In vivo, female BALB/c mice infected with L. major were treated with polar fractions. Lesion size was monitored weekly, and at the end of treatment, parasite load at lesion margins and seven liver biochemical parameters in serum were measured.
RESULTS: Polar fractions exhibited mild-to-moderate antileishmanial effects on promastigotes without significant cytotoxicity to macrophages. In vivo, treatment with 20 mg/kg C. platycarpos, 20 mg/kg C. flava, and 80 mg/kg of the mixture significantly reduced lesion size compared to controls. Clinical observations also indicated reduced local inflammation in these groups. Parasite load remained detectable across all groups, and liver biochemical parameters did not differ significantly from the negative control.
CONCLUSION: Polar fractions of the studied plants demonstrated safety and therapeutic promise, supporting their potential as adjunctive candidates for further investigation in the management of CL caused by L. major.